Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models.
Saved in:
| Title: | Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models. |
|---|---|
| Authors: | Wang SH; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Serr I; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany., Digigow R; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Metzler B; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Surnov A; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany., Gottwick C; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Alsamman M; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Krzikalla D; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Heine M; Department of Biochemistry and Molecular Cell Biology (N30), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Zahlten M; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Widera A; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Mungalpara D; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Şeleci M; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Fanzutti M; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Marques Mesquita LM; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Vocaturo AL; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Herkel J; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.; Hamburg Centre for Translational Immunology (HCTI), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Carambia A; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Schröter C; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Sarko D; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Pohlner J; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Daniel C; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Division of Clinical Pharmacology, Department of Medicine IV, Ludwig Maximilian University of Munich, Munich, Germany., de Min C; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Fleischer S; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Mar 17; Vol. 16, pp. 1542380. Date of Electronic Publication: 2025 Mar 17 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1542380 |
